Rhinosectan® spray (containing xyloglucan) on the ciliary function of the nasal respiratory epithelium; results of an in vitro study

Abstract

BackgroundTo assess the effects of Rhinosectan® spray, a medical device containing xyloglucan, on nasal ciliary function (in MucilAir™Nasal cells).MethodsMucilAir™Nasal, a three-dimensional organotypic airway tissue model (with different cell types), was treated with Rhinosectan® (30 µl) or with a control (saline solution). The effects of Rhinosectan® were evaluated at 15 and 60 min post-exposure by: measurement of the cilia beating frequency (Hz), mucin detection (Enzyme-Linked Lectin Assay—ELLA), mucociliary clearance (µm/s) and phagocytosis assay (fluorescence).ResultsExposure of MucilAir™ to Rhinosectan® did not alter the cilia beating frequency at 15 and 60 min post-exposure (diluted and undiluted). Exposure to Rhinosectan® (undiluted) during 60 min increased mucociliary clearance (93.3 ± 2.1 µm/s vs. 80.9 ± 1.8 µm/s; p < 0.01) and phagocytic activity (1.89-fold increase) in comparison with saline solution. Moreover, a significant decrease in mucin concentration was observed after 15 min of exposure (171.4 ng/ml vs. 306.5 ng/ml; p < 0.01) and at 60 min post-treatment (242.7 ng/ml vs. 339 ng/ml; p < 0.05).ConclusionsThe application of Rhinosectan® to nasal epithelial cells does not impair ciliary movement, enhances mucociliary clearance and facilitates phagocytosis while reducing mucin secretion, which are optimal properties for the management of rhinitis and associated conditions.

Health Benefits of Heat-Killed (Tyndallized) Probiotics: An Overview

“…Topical application of heat-killed bacteria could have also a role in the management of allergic respiratory diseases, based on the favorable results obtained with mucosal protectors in nasal in vitro models [142,144].…”

“…The protective properties of tyndallized probiotics plus other mucosal protectors, such as xyloglucan, should deserve further research, in intestinal cells and also in other models, as nasal epithelial cells, based on the previous studies supporting the use of xyloglucan as protector of the nasal mucosal epithelial cells [143,144]. In fact, xyloglucan in nasal formulations is an innovative strategy for the management of nasal disorders, as rhinitis and rhinosinusitis, based on their protective properties on the nasal epithelial cells, maintaining the barrier integrity and allowing the avoidance of allergens and triggering factors, as demonstrated in MucilAir™Nasal cells [4,143,144] and in patients with rhinosinusitis [145].…”

Replacement Strategies for Animal Studies in Inhalation Testing

“…In spheroids, vascularization and cellular crosstalk are particularly relevant [60]. Reconstructed tissues/ex vivo samples are used to assess cilia beating frequency, mucus production, airway surface liquid volume, mucociliary clearance [61]. Effects on alveolar macrophages can be assessed by measuring of chemotaxis, phagocytosis and phospholipidosis [62].…”

Evaluating the Protective Properties of a Xyloglucan-Based Nasal Spray in a Mouse Model of Allergic Rhinitis

“…An in vitro study that used a three-dimensional organotypic airway tissue model (with different cell types) treated with XG, showed that the application of XG to nasal epithelial cells did not impair ciliary movement, enhanced mucociliary clearance and facilitated phagocytosis while reducing mucin secretion, properties which are favorable for the management of rhinitis and associated conditions [ 18 ].…”